Deu Edgar, Leyva Melissa J, Albrow Victoria E, Rice Mark J, Ellman Jonathan A, Bogyo Matthew
Department of Pathology, Stanford School of Medicine, 300 Pasteur Drive, Stanford, CA 94305, USA.
Chem Biol. 2010 Aug 27;17(8):808-19. doi: 10.1016/j.chembiol.2010.06.007.
The widespread resistance of malaria parasites to all affordable drugs has made the identification of new targets urgent. Dipeptidyl aminopeptidases (DPAPs) represent potentially valuable new targets that are involved in hemoglobin degradation (DPAP1) and parasite egress (DPAP3). Here we use activity-based probes to demonstrate that specific inhibition of DPAP1 by a small molecule results in the formation of an immature trophozoite that leads to parasite death. Using computational methods, we designed stable, nonpeptidic covalent inhibitors that kill Plasmodium falciparum at low nanomolar concentrations. These compounds show signs of slowing parasite growth in a murine model of malaria, which suggests that DPAP1 might be a viable antimalarial target. Interestingly, we found that resynthesis and activation of DPAP1 after inhibition is rapid, suggesting that effective drugs would need to sustain DPAP1 inhibition for a period of 2-3 hr.
疟原虫对所有平价药物的广泛耐药性使得确定新靶点变得紧迫。二肽基氨肽酶(DPAPs)是具有潜在价值的新靶点,它们参与血红蛋白降解(DPAP1)和疟原虫逸出(DPAP3)。在此,我们使用基于活性的探针证明,小分子对DPAP1的特异性抑制会导致未成熟滋养体的形成,进而导致疟原虫死亡。通过计算方法,我们设计出了稳定的非肽类共价抑制剂,它们在低纳摩尔浓度下就能杀死恶性疟原虫。这些化合物在疟疾小鼠模型中显示出减缓疟原虫生长的迹象,这表明DPAP1可能是一个可行的抗疟靶点。有趣的是,我们发现抑制后DPAP1的重新合成和激活很快,这表明有效的药物需要将DPAP1的抑制维持2至3小时。